ImmunoGen, Inc. (IMGN)
(Delayed Data from NSDQ)
$2.88 USD
+0.38 (15.20%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.93 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.88 USD
+0.38 (15.20%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.93 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Corvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up
by Zacks Equity Research
Corvus' (CRVS) lead candidate, soquelitinib, gets orphan drug designation in the United States. The company???s shares rise 10.75% on the news.
Humacyte (HUMA) Up on HAV BLA Priority Tag for Vascular Trauma
by Zacks Equity Research
Humacyte (HUMA) gains 16% as the FDA accepts its BLA for the HAV bioengineered tissue to treat vascular trauma under Priority Review. A final decision is expected in August 2024.
Ionis' (IONS) Eplontersen Gets Fast Track Tag for New Indication
by Zacks Equity Research
The FDA bestows a Fast Track designation to Ionis (IONS) and partner AstraZeneca's (AZN) eplontersen for treating adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
Foghorn (FHTX) Jumps 55% as Lilly Takes Up FHD-909 Development
by Zacks Equity Research
Foghorn (FHTX) gains 55% as its strategic collaboration partner, Lilly, selects the pre-clinical candidate, FHD-909, for clinical development.
Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how ImmunoGen (IMGN) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.
ImmunoGen (IMGN) Soars 5.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
ImmunoGen (IMGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Bristol Myers' (BMY) Opdivo Label Expansion Filings Get Accepted
by Zacks Equity Research
Bristol Myers (BMY) announces the acceptance of its regulatory filings for the perioperative Opdivo regimen to treat a lung cancer indication in the United States and EU.
JAZZ Boosts Oncology Pipeline With KRAS Inhibitor Program
by Zacks Equity Research
JAZZ inks a deal to acquire global rights to Redx Pharma's KRAS inhibitor program to strengthen its early-stage oncology pipeline.
REGENXBIO's (RGNX) Hunter Syndrome Study Meets Goal, Stock Up
by Zacks Equity Research
REGENXBIO (RGNX) gains 12% on positive top-line results from the phase I/II/III study of its investigational one-time gene therapy candidate, RGX-121, to treat pediatric patients with Hunter syndrome.
Deciphera (DCPH) Q4 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Deciphera (DCPH) reports better-than-expected fourth-quarter 2023 results, wherein both earnings and revenues beat their respective estimates, driven by increased Qinlock sales.
Should First Trust Mid Cap Core AlphaDEX ETF (FNX) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FNX
Is First Trust Mid Cap Core AlphaDEX ETF (FNX) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FNX
Gilead (GILD) Down as NSCLC Study Fails to Meet Primary Goal
by Zacks Equity Research
Gilead Sciences' (GILD) phase III study evaluating Trodelvy (sacituzumab govitecan) in previously treated metastatic NSCLC fails to meet its primary endpoint. Shares decline on the same.
Should First Trust Mid Cap Growth AlphaDEX ETF (FNY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FNY
Should JPMorgan BetaBuilders U.S. Small Cap Equity ETF (BBSC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for BBSC
How ImmunoGen (IMGN) Stock Stands Out in a Strong Industry
by Zacks Equity Research
ImmunoGen (IMGN) has seen solid earnings estimate revision activity over the past two month, and belongs to a strong industry as well.
All You Need to Know About ImmunoGen (IMGN) Rating Upgrade to Strong Buy
by Zacks Equity Research
ImmunoGen (IMGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Best Momentum Stocks to Buy for January 4th
by Zacks Equity Research
IMGN and GTLB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 4, 2024.
New Strong Buy Stocks for January 4th
by Zacks Equity Research
IMGN, GTLB, FNWD, BL and TMHC have been added to the Zacks Rank #1 (Strong Buy) List on January 4, 2024.
Is Arvinas (ARVN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Arvinas, Inc. (ARVN) and ImmunoGen (IMGN) have performed compared to their sector so far this year.
5 Reasons to be Bullish into 2024
by Andrew Rocco
Stock Strategist Andrew Rocco unveils 5 bullish undercurrents that will push stocks even higher into the new year.
Beat the Market the Zacks Way: Shopify, Lululemon, Telos in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Why Is Esperion Therapeutics (ESPR) Up 51.4% Since Last Earnings Report?
by Zacks Equity Research
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AbbVie (ABBV) to Acquire Cerevel Therapeutics (CERE) for $8.7B
by Zacks Equity Research
AbbVie (ABBV) offers to buy Cerevel Therapeutics (CERE) for $8.7 billion. The acquisition will strengthen AbbVie's neuroscience pipeline.
ImmunoGen (IMGN) Gets FDA Priority Review for Elahere sBLA
by Zacks Equity Research
The FDA grants priority review to ImmunoGen's (IMGN) sBLA to convert the accelerated approval for Elahere to full approval for treating platinum-resistant ovarian cancer. A decision is due on Apr 5, 2024.